Publications by authors named "Keiyu Matsumoto"

Introduction: Antiphospholipid syndrome is an autoimmune disease that presents with thrombus hyperplasia. Although very rare, this disease is reported to become severe after the surgical invasion and other interventions. To our knowledge, there are no reports of partial nephrectomy in patients with antiphospholipid.

View Article and Find Full Text PDF

Background/aim: Standard chemotherapy for advanced urothelial carcinoma (UC) patients with moderate renal dysfunction has not yet been established.

Patients And Methods: We retrospectively assessed outcomes of patients with advanced UC who underwent first-line chemotherapy with full-/reduced-dose gemcitabine plus cisplatin (GC-f/GC-r) or full-/reduced-dose gemcitabine plus carboplatin (G-Car-f/G-Car-r) according to renal function.

Results: Seventy-eight patients were included in this study.

View Article and Find Full Text PDF

Overcoming cisplatin (CDDP) resistance is a major issue in urothelial cancer (UC), in which CDDP-based chemotherapy is the first-line treatment. WEE1, a G /M checkpoint kinase, confers chemoresistance in response to genotoxic agents. However, the efficacy of WEE1 blockade in UC has not been reported.

View Article and Find Full Text PDF

The biological processes of urothelial carcinogenesis are not fully understood, particularly regarding the relationship between specific genetic events, cell of origin, and molecular subtypes of subsequent tumors. N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)-induced mouse bladder cancer is widely accepted as a useful model that recapitulates the pathway of human bladder tumorigenesis from dysplasia to invasive cancer via carcinoma in situ. However, the long and variable time of tumorigenesis often hinders efficient preclinical or translational research.

View Article and Find Full Text PDF

Adeno-associated virus (AAV) vectors have been recognized as promising tools for gene delivery. The bladder is a seemingly ideal organ for virus transfer, with easy access through the urethra enabling organ-specific delivery. However, achieving adequate transduction efficiency in the urothelium has been a major challenge because of the barrier function of the glycosaminoglycan (GAG) layer.

View Article and Find Full Text PDF

Background: Since the standard gemcitabine and cisplatin (GC) chemotherapy for advanced bladder cancer yields limited therapeutic effect due to chemoresistance, it is a clinical challenge to enhance sensitivity to GC.

Methods: We performed high-throughput screening by using a library of known chemicals and repositionable drugs. A total of 2098 compounds were administered alone or with GC to human bladder cancer cells, and chemicals that enhanced GC effects were screened.

View Article and Find Full Text PDF

The success of immunotherapy using immune checkpoint inhibitors has changed the practice of cancer treatment tremendously. However, there are still many clinical challenges, such as drug resistance, predictive biomarker development, exploration of combination therapies, and prediction of immune-related adverse events in preclinical settings. To overcome these problems, it is essential to establish faithful preclinical mouse models that recapitulate the clinical features, molecular genetics, biological heterogeneity, and immune microenvironment of human cancers.

View Article and Find Full Text PDF

Background: Non-muscle-invasive bladder cancer (NMIBC) can be treated using transurethral resection (TUR), but high incidence of intravesical recurrence remains a clinical challenge. Single immediate postoperative instillation of chemotherapy (IPIOC) is controversial for NMIBC patients with intermediate recurrence risk. The aim of the present study was to report the efficacy and toxicity of IPIOC, particularly in intermediate-risk NMIBC patients, in the real-world setting.

View Article and Find Full Text PDF

Introduction: Non-islet cell tumor hypoglycemia is a rare paraneoplastic syndrome associated with tumors. Although it mainly occurs in solid tumors of mesenchymal and epithelial origin, but rarely also in hematopoietic and neuroendocrine origin.

Case Presentation: We describe a 65-year-old man with a muscle-invasive bladder urothelial carcinoma, which rapidly progressed against systemic chemotherapy consisting of gemcitabine and cisplatin.

View Article and Find Full Text PDF

Peritoneal tuberculosis (TB) is a relatively uncommon presentation of extrapulmonary TB. Early diagnosis of peritoneal TB is difficult because of its nonspecific clinical manifestation such as abdominal pain, fever, or ascites. Especially early after surgery of abdomen or pelvis, these symptoms can be misdiagnosed as septic peritonitis.

View Article and Find Full Text PDF

Urosepsis is not uncommon and sometimes causes a critical condition including death. We retrospectivelyanaly zed the risk factors for mortalityin urosepsis. We treated 80 patients as urosepsis from 2010 to 2014 in our hospital.

View Article and Find Full Text PDF

A 69-year-old man with left atrophic kidney was referred to our hospital because of a 5.7 cm solid mass in the lower pole of right kidney revealed by computed tomography for evaluation of aortic aneurysm. An open transperitoneal partial nephrectomy was performed, and final pathological diagnosis was clear cell carcinoma, grade 2, pT1b, pNx.

View Article and Find Full Text PDF

Introduction: Immediate postoperative instillation of chemotherapy to prevent intravesical recurrence of nonmuscle invasive bladder cancer is supported by level 1 evidence and recommended by contemporary guidelines. However, there have been a few reports on the feasibility and adherence of immediate postoperative chemotherapy instillation after transurethral resection. We retrospectively assessed the adherence rate of this treatment in patients with nonmuscle invasive bladder cancer.

View Article and Find Full Text PDF

We compared the efficacy of naftopidil monotherapy with combination therapy using tamsulosin hydrochloride and solifenacin succinate in the treatment of lower urinary tract symptoms (LUTS) with overactive bladder (OAB) secondary to benign prostatic hyperplasia (BPH). Thirty one patients were enrolled in a randomized crossover study. Fourteen patients were initially prescribed naftopidil 75 mg (N) for 8 weeks, followed by tamsulosin 0.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on the effectiveness of combining external-beam radiotherapy (EBRT) with neoadjuvant androgen deprivation therapy (NeoADT) for patients with high-risk prostate cancer, as categorized by NCCN guidelines.
  • A total of 70 high-risk patients received treatment from 2002 to 2013, with follow-up showing that biochemical progression-free survival (bPFS) rates were significantly affected by the number of risk factors and pre-treatment PSA levels.
  • After a median follow-up of 4.8 years, the results indicated a 5-year bPFS of 63% and an 8-year overall survival (OS) rate of 91
View Article and Find Full Text PDF

Purpose: We investigated the impact of lower urinary tract symptoms (LUTS) on generic health-related quality of life (HRQOL) in male patients without co-morbidity.

Patients And Method: From 2003 to 2011, a total 567 men who presented out urological department completed the questionnaires including International Prostate Symptom Score (IPSS), incontinence-frequency score (IFS) from the UCLA prostate cancer index, MOS 36-Item Short-Form Health Survey (SF-36). Among 230 patients with no coexisting morbidity, the relations between each LUTS score of IPSS indices and IFS and 8 domain scores of SF-36 were analyzed by Pearson's product-moment correlation and stepwise multiple regression analysis.

View Article and Find Full Text PDF
Article Synopsis
  • A 20-year-old man with end-stage renal disease underwent an ABO-incompatible kidney transplant from his mother and received immunosuppressive therapy including mycophenolate mofetil (MMF) prior to the surgery.
  • His dosage of MMF was reduced due to diarrhea and he received rituximab, leading to a significant drop in neutrophil (Neu) count post-operation, prompting the use of granulocyte colony-stimulating factor.
  • Although MMF-induced neutropenia typically occurs later in transplant patients, this case is notable as it happened immediately post-transplant, highlighting the need for careful monitoring of MMF dosage and side effects.
View Article and Find Full Text PDF

We prospectively investigated the safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) in 24 patients (22 males, 2 females ; age range 39-86 years, median 64 years) with metastatic renal cell carcinoma (RCC). During the observation period (3-62 weeks, median 21 weeks), thrombocytopenia was seen in 13 (54.2%), leukopenia in 11 (45.

View Article and Find Full Text PDF
Article Synopsis
  • * Patients showed significant improvements in urinary symptoms, with International Prostate Symptom Scores dropping from 21 to 6 and maximum flow rates increasing from 6.8 ml/s to 17.4 ml/s post-surgery.
  • * Although transient urinary incontinence occurred in 28.5% of patients and one had a serious complication, HoLEP was overall deemed safe and effective, suggesting it could become a new standard treatment for BPH.
View Article and Find Full Text PDF

We report a case of the rechallenge of everolimus for metastatic renal cell carcinoma (RCC) after successful recovery from grade 3 interstitial lung disease (ILD). A 76-year-old man with metastatic RCC developed grade 3 ILD one month after the initiation of everolimus therapy (10 mg/day). ILD subsided in 4 months after the withdrawal of everolimus and treatment with corticosteroids.

View Article and Find Full Text PDF
Article Synopsis
  • The TNM classification for renal cell carcinoma was updated in 2009, defining T3a tumors as those with involvement of the renal vein or fat invasion.
  • A study reviewed 89 patients with pT3aN0M0 renal cell carcinoma who had surgery from 1992-2011 to analyze risk factors for recurrence, with key findings showing a five-year recurrence-free survival rate of 69%.
  • Significant factors influencing recurrence included tumor size, grade, infiltrative growth (INF), and renal vein thrombus, with INF identified as an independent risk factor, particularly affecting prognosis for patients with both fat invasion and renal vein thrombus.
View Article and Find Full Text PDF

Twenty-four patients with metastatic urothelial carcinoma of bladder (11) and upper urinary tract (13) received gemcitabine 1,000 mg/m2 on days 1, 8, and 15, and cisplatin 70 mg/m2 (GC) or carboplatin area under the serum concentration-time curve (AUC) 5 (GCarbo) on day 2, every 28 days. One to 13 chemotherapy cycles (median number, 4) per patient were administered. Three patients (12.

View Article and Find Full Text PDF

We report a case of granulocyte-colony-stimulating factor (G-CSF)-producing carcinoma of collecting ducts of Bellini. A 62-year-old male was admitted to our hospital with the chief complaint of high grade fever,right flank pain and general malaise. The white blood cell count and serum G-CSF concentration were elevated to 20,100/ μ l and 140 pg/ml,respectively.

View Article and Find Full Text PDF